{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen Y"],"funding":["Science Foundation of the Postdoctoral Department of Heilongjiang Province","Program of Science and Technology of Sichuan Province","Haiyan Research Funding of the Harbin Medical University Cancer Hospital"],"pagination":["11"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9875443"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common mutation types. BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (Class3). We retrospectively reviewed the mutational profiles of 328 treatment-naïve colorectal tumors with BRAF mutations detected using capture-based hybrid next-generation sequencing targeting 400 + cancer-related genes. The clinical and genetic distinctions of patients harboring Class1/2/3 BRAF mutations were investigated, which revealed that tumors with Class1 BRAF mutations showed more unique genomic profiles than those with Class2/3 mutations. Also, by using an external dataset from cBioPor"],"journal":["Biomarker research"],"pubmed_title":["The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses."],"pmcid":["PMC9875443"],"funding_grant_id":["JJZD2021-03","2021YFQ0037","LBH-Q21118"],"pubmed_authors":["Wu M","Lin T","Huang H","Zhang H","Wu C","Ma Y","Gu A","Liang C","Liu Y","Ou Q","E M","Shao Y","Zhang Y","Ye S","Guo H","Weng H","Chen Y","Pu X","Chen X","Sun H","Deng Y","Wu X"],"additional_accession":[]},"is_claimable":false,"name":"The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses.","description":"BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common mutation types. BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (Class3). We retrospectively reviewed the mutational profiles of 328 treatment-naïve colorectal tumors with BRAF mutations detected using capture-based hybrid next-generation sequencing targeting 400 + cancer-related genes. The clinical and genetic distinctions of patients harboring Class1/2/3 BRAF mutations were investigated, which revealed that tumors with Class1 BRAF mutations showed more unique genomic profiles than those with Class2/3 mutations. Also, by using an external dataset from cBioPor","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-05-29T05:32:59.256Z","creation":"2025-02-18T23:45:00.211Z"},"accession":"S-EPMC9875443","cross_references":{"pubmed":["36694231"],"doi":["10.1186/s40364-022-00443-8"]}}